Veraxa Biotech AG VRXA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.95 down $0.00, 0.23% at close Nov 6
Last close · Previous close $0.95
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$5.84Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.95down $0.00, 0.23%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.95Nov 5
- Volume222.34KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume266.28KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.90 to $27.36; now $0.95
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VRXA trailed the S&P 500 in both periods.
| Period | VRXA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VRXA: down 12.0% S&P 500: down 5.6% | VRXA trailed the S&P 500 by 6.4 percentage points Trailed |
| 3M | VRXA: down 48.9% S&P 500: down 4.1% | VRXA trailed the S&P 500 by 44.8 percentage points Trailed |
VRXA trailed the S&P 500 in both periods.
| Period | VRXA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VRXA: down 12.0% S&P 500: down 5.6% | VRXA trailed the S&P 500 by 6.4 percentage points Trailed |
| 3M | VRXA: down 48.9% S&P 500: down 4.3% | VRXA trailed the S&P 500 by 44.6 percentage points Trailed |
All-time high
$24.79
Closing high on . Now 96.2% below that record.
Split-adjusted daily closes since Jun 11, 2026.
Stock splits
VRXA hasn’t split since its price history begins in 2026.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY25, the quarter ended Dec 31, 2025. “Last 12 months” means the four quarters from Jan 1, 2025 to Dec 31, 2025, and balance-sheet figures are as of Dec 31, 2025.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $29.65K
- Net income
- −$84.91M
- Diluted EPS
- −$5.84
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY24 (Mar 31, 2024) | $0.00 | −$73.92K | −$0.01 |
| Q2 FY24 (Jun 30, 2024) | $0.00 | −$70.57K | −$0.01 |
| Q3 FY24 (Sep 30, 2024) | $0.00 | $1.94M | $0.10 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$32.95M | −$2.39 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | $3.46M | $0.11 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | $3.80M | $0.12 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | $3.69M | $0.11 |
| Q4 FY25 (Dec 31, 2025) | $29.65K | −$95.85M | −$6.19 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY24 (Dec 31, 2024) | $0.00 | −$31.26M | −$2.22 |
| FY25 (Dec 31, 2025) | $29.65K | −$84.32M | −$5.82 |
Margins
- Gross 66.0%
- Operating −282,444.0%
- Net −286,330.8%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$13.03MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$12.48MLast 12 months
- Capital spending$553.39KLast 12 months
- −43,957.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $7.29MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.04MAs of Dec 31, 2025
Cash plus short- and long-term marketable securities on the Dec 31, 2025 balance sheet.
- Total debt$2.71MAs of Dec 31, 2025
- Net debt$666.66KAs of Dec 31, 2025
- 0.44As of Dec 31, 2025
Current assets divided by current liabilities on the Dec 31, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −26.2%Last 12 months
Over the last 12 months, Veraxa Biotech’s net loss was 26.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Veraxa Biotech AG
Veraxa Biotech AG
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VRXA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VRXA stock FAQ
What is VRXA stock’s price today?
Veraxa Biotech (VRXA) traded at $0.95 at the close on , unchanged from the previous close of $0.95. Over the past 52 weeks it has traded between $0.90 and $27.36.
What is VRXA’s P/E ratio?
VRXA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$5.84).
How much revenue does Veraxa Biotech make?
Veraxa Biotech reported $29.7 thousand of revenue over the four quarters to . In its latest quarter (Q4 FY25, ended ) revenue was $29.7 thousand.
Is Veraxa Biotech profitable?
Not over the four quarters to . Veraxa Biotech reported a net loss of $84.9 million across those four quarters on $29.7 thousand of revenue.
What are VRXA’s earnings per share?
VRXA’s diluted earnings per share were −$5.84 over the four quarters to , compared with −$2.31 in the twelve months before. The latest quarter (Q4 FY25) brought −$6.19 per share, against −$2.39 a year earlier (how EPS works).
Does VRXA pay a dividend?
Veraxa Biotech hasn’t paid a dividend in the last twelve months.
What is VRXA’s 52-week high and low?
Over the past 52 weeks VRXA has traded as low as $0.90 and as high as $27.36. At $0.95 at the close on , it is 96.5% below that high and 5.6% above the low.
What is VRXA’s all-time high?
VRXA’s highest closing price was $24.79 on , adjusted for stock splits. At $0.95 at the close on , it is 96.2% below that record.
Has VRXA stock ever split?
No. VRXA hasn’t split since its price history begins in 2026.
What sector and industry is Veraxa Biotech in?
Veraxa Biotech is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
What exchange does VRXA trade on?
Veraxa Biotech trades on the Nasdaq under the ticker symbol VRXA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.